Source: International Congress 2018 – Lung cancer: personalised medicine
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Jovanovic (Belgrade, Republic of Serbia), J. Kotur Stevuljevic (Belgrade, Republic of Serbia), M. Roksandic-Milenkovic (Belgrade, Republic of Serbia), M. Simon (Cluj Našpoca, Romania), V. Ceriman (Belgrade, Republic of Serbia), S. Popevic (Belgrade, Republic of Serbia), I. Vukanic (Belgrade, Republic of Serbia), N. Samardžic (Belgrade, Republic of Serbia), M. Kontic (Belgrade, Republic of Serbia), B. Ilic (Belgrade, Republic of Serbia). Soluble sPD-L1 plasma concentrations in a series of 95 lung cancer patients. 2218

Member's Comments

No comment yet.

Related content which might interest you: Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Elevated endogenous thrombin potential in patients with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 199s Year: 2003 Evaluation of serum levels of Sirtuin-1 in lung cancer patients Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Serum levels of TGFβ and VEGF in lung cancer patients and healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 43s Year: 2004 Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 Plasma D-dimer level and stage of primary lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003 Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001 Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003 Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 The clinical significance of serum interleukin 18 concentration in lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 394s Year: 2003 The study on the association of serum C-reactive protein level with the risk of lung cancer Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009 Serum levels of STR-3 and TIMP-2 in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Serum levels of sFas and sFasL during chemotherapy of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005 Clinical value of measurements of interleukin-2 soluble receptor in blood of lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002 Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 The role of iron and transferrin serum levels in lung cancer patients - a single institution experience Source: Eur Respir J 2005; 26: Suppl. 49, 330s Year: 2005 Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011